Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesWound CareSummaCare Skin Substitute Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Tissue-Engineered Skin Substitutes

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and medical-necessity criteria for tissue-engineered skin substitutes and related bioengineered skin or soft-tissue matrices used for breast reconstruction, burn wounds, diabetic foot ulcers, venous stasis ulcers, and specified wound conditions in commercial members.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerSummaCare
    PolicyTissue-Engineered Skin Substitutes
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date02/12/2026
    Next Review DateN/A
    Key ActionBefore initiating specialized wound therapy, document chronicity, failed standard care, wound characteristics, medical necessity, and the planned product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30%Epicel burn coverage minimum
    <12%Required HbA1c
    ABI ≥0.70Adequate foot blood supply
    10Maximum CTP applications
    1 yearRetreatment interval

    Covered Uses and Medical Necessity Requirements

    Breast Reconstruction

    Covered when associated with a covered, medically necessary reconstruction procedure.

    AlloDerm, AlloMax, Cortiva, DermACELL, and FlexHD are medically necessary when used in association with a covered, medically necessary breast reconstruction procedure.

    Biobrane or Biobrane L

    Covered when used for temporary covering of an eligible burn wound.

    Biobrane or Biobrane L is used for temporary covering of a partial-thickness, freshly debrided or excised burn wound.

    Epicel

    Covered when ALL of the following are met:

    ALL of the following

    • Used according to the FDA-approved Humanitarian Device Exemption for an individual with deep dermal or full-thickness burns comprising a total body surface area of at least 30%.
    • May be used with split-thickness autografts, or alone when split-thickness autografts are not an option because of the severity and extent of the burns.

      This describes permitted use with or without autografting.

    Integra Burn Products

    Covered when BOTH of the following criteria are met:

    ALL of the following

    • Postexcisional treatment of a full-thickness or deep partial-thickness burn.
    • Sufficient autograft is not available at the time of excision or is contraindicated.

    Transcyte

    Covered when used as a temporary covering before autografting.

    Used for temporary covering of a surgically excised deep partial-thickness or full-thickness burn wound before autografting.

    Dermagraft

    Covered when ALL applicable criteria are met:

    ALL of the following

    • ONE of

      • Full-thickness diabetic foot ulcer of more than 6 weeks' duration extending through the dermis without tendon, muscle, joint capsule, or bone exposure.
      • Wound related to dystrophic epidermolysis bullosa.
    • Initial treatment is limited to 3–4 applications.
    • Additional applications are limited to a maximum of 8 in 12 weeks and require evidence of wound healing.
    • Used with standard wound-care regimens.

    AlloPatch (Pliable)

    Covered when ALL of the following are met:

    ALL of the following

    • Partial- or full-thickness diabetic foot ulcer of more than 6 weeks' duration with no capsule, tendon, or bone exposed.
    • Used in conjunction with standard diabetic-ulcer care.
    • Initial treatment is limited to 3–4 applications.
    • Additional applications are limited to a maximum of 8 in 12 weeks and require evidence of wound healing, such as epithelialization or reduction in ulcer size.

    EpiFix Amniotic Membrane

    Covered when at least ONE of the following pathways is met:

    ALL of the following

    • ONE of

      • Partial- or full-thickness neuropathic diabetic foot ulcer of more than 6 weeks' duration with no capsule, tendon, or bone exposed, used with standard diabetic-ulcer care.
      • Difficult-to-heal chronic venous or diabetic partial- or full-thickness lower-extremity ulcer that has failed standard wound therapy for at least 4 weeks.
    • Initial treatment is limited to 3–4 applications.
    • Additional applications may be made at least 1 week apart, up to 4 in 12 weeks, when evidence of wound healing is present.

    DermaCell

    Covered when at least ONE of the following indications is met:

    ALL of the following

    • ONE of

      • Partial- or full-thickness neuropathic diabetic foot ulcer of more than 6 weeks' duration with no capsule, tendon, or bone exposed, used with standard diabetic-ulcer care.
      • Oro-nasal fistula following cleft-palate repair.
    • Initial treatment is limited to 3–4 applications.
    • Applications beyond 12 weeks are not medically necessary regardless of wound status.

    Grafix

    Covered when ALL of the following are met:

    ALL of the following

    • Partial- or full-thickness neuropathic diabetic foot ulcer of more than 6 weeks' duration with no capsule, tendon, or bone exposed.
    • Used in conjunction with standard diabetic-ulcer care.
    • Initial treatment is limited to 3–4 applications.
    • Additional applications may be made at least 1 week apart, up to 6 in 12 weeks, when evidence of wound healing is present.

    Graft Jacket Regenerative Tissue Matrix

    Covered when at least ONE of the following indications is met:

    ONE of

    • Full-thickness diabetic foot ulcer of more than 6 weeks' duration extending through the dermis without tendon, muscle, joint capsule, or bone exposure.
    • Oro-nasal fistula following cleft-palate repair.

    Integra Diabetic-Foot Products

    Covered for eligible neuropathic diabetic foot ulcers.

    ALL of the following

    • Partial- or full-thickness neuropathic diabetic foot ulcer of more than 6 weeks' duration with no capsule, tendon, or bone exposed.
    • Used in conjunction with standard diabetic-ulcer care.

    Oasis Wound Matrix and Ultra Tri-Layer Matrix

    Covered when the applicable diabetic-foot or venous-stasis pathway criteria are met.

    ONE of

    • Diabetic foot ulcer

      • Partial- or full-thickness neuropathic diabetic foot ulcer of more than 6 weeks' duration with no capsule, tendon, or bone exposed.
      • Used in conjunction with standard diabetic-ulcer care.
      • Initial treatment is limited to up to 4 applications.
      • Additional applications may be made at least 1 week apart, up to 4 in 12 weeks, when evidence of wound healing is present.
    • Venous stasis ulcer

    Additional Criteria for All Diabetic Foot Ulcers

    These criteria apply to all diabetic foot ulcers:

    ALL of the following

    • For type 1 and type 2 diabetes, HbA1c is less than 12%.
    • The treated foot has adequate blood supply, evidenced by a palpable pedal pulse or ABI of at least 0.70.

    Oasis Venous Stasis Ulcers

    Oasis treatment for venous stasis ulcers is covered when ALL applicable medical-necessity criteria are met:

    ALL of the following

    • Difficult-to-heal chronic partial- or full-thickness venous ulcer of the lower extremity.
    • The venous stasis ulcer has been present for at least 3 months and has failed appropriate wound care for at least 30 days, with documented compliance.
    • Standard wound therapy has failed; documentation identifies the specific interventions that failed and supports a comprehensive treatment plan before therapy begins.
    • The wound is clean and free of infection, osteomyelitis, necrotic debris, and exudate, with underlying infection, cellulitis, osteomyelitis, foreign body, or malignant process treated and resolved before CTP therapy.
    • The ulcer is a partial- or full-thickness ulcer with a clean granular base, is at least 1.0 cm², and does not involve exposed tendon, muscle, joint capsule, bone, or sinus tract unless the product labeling allows such involvement.

    Medicare Lower-Extremity CTP Coverage Criteria

    Medicare lower-extremity CTP coverage requires ALL applicable criteria to be met:

    ALL of the following

    • The wound is chronic and has failed organized, comprehensive conservative therapy for at least 30 days.
    • The wound has failed documented appropriate wound-care measures, increased in size or depth, or remained unchanged without indication that improvement is likely.
    • The ulcer is partial- or full-thickness, at least 1.0 cm², has a clean granular base, and does not involve tendon, muscle, joint capsule, exposed bone, or sinus tracts unless the product label permits those features.
    • The wound is clean and free of necrotic debris or exudate and has adequate circulation and oxygenation.
    • For diabetic foot ulcers, the record documents type 1 or type 2 diabetes and medical management.

    General CTP Utilization Requirements

    CTP use must satisfy ALL applicable utilization and medical-necessity requirements:

    ALL of the following

    • The medical record documents use within a comprehensive, organized wound-management program.
    • The product is FDA-labeled or cleared for the type of wound being treated.
    • The treatment is safe and effective, appropriate in duration and frequency, furnished in an appropriate setting by qualified personnel, and does not exceed the patient's medical needs.
    • The treatment is at least as beneficial as an existing and available medically appropriate alternative.
    • The episode does not exceed applicable product-label, policy, or Medicare application limits.

    General Medical Necessity

    A service is reasonable and necessary only when ALL of the following standards are satisfied:

    ALL of the following

    • Safe and effective.
    • Not experimental or investigational, except qualifying routine clinical-trial costs covered under applicable Medicare requirements.
    • Appropriate in duration and frequency and furnished according to accepted standards of medical practice.
    • Provided in a setting appropriate to the patient's medical needs and condition.
    • Ordered and furnished by qualified personnel.

    Product Eligibility

    The requested product must meet ALL product-specific FDA requirements, including at least ONE of the following:

    ALL of the following

    • ONE of

      • FDA premarket approval for the requested indication.
      • FDA 510(k) premarket clearance for the requested indication.
      • FDA Humanitarian Device Exemption for the requested indication.

    Not Reasonable and Necessary Applications

    The following applications are not reasonable and necessary:

    ANY of the following

    • More than 8 applications of a skin-substitute graft or CTP within an episode of care of up to 16 weeks.
    • Repeat applications after unsuccessful treatment.
    • Application when underlying conditions or exacerbating factors are inadequately controlled, including active infection, progressive necrosis, active Charcot arthropathy, active vasculitis, or ischemia.
    • Surgical preparation services performed with routine, simple, or repeat skin-replacement therapy.
    • Liquid or gel skin-substitute products or CTPs for ulcer care.

    Experimental, Investigational, or Unproven Use

    The requested use is not covered when it falls outside an established eligible indication or product list.

    ANY of the following

    • A listed product is used for an unlisted indication; such use is experimental, investigational, or unproven.
    • A skin-substitute product is not listed in the policy; it is experimental, investigational, or unproven for any indication.

    Dermagraft is not medically necessary when the involved foot has an inadequate blood supply. Dermagraft is contraindicated and has no proven value in infected ulcers or ulcers with sinus tracts.

    Applications of DermaCell or Oasis beyond 12 weeks are not medically necessary regardless of wound status.

    Partial-thickness wounds with retained epithelial appendages are not candidates for grafting or replacement because the epithelium can repopulate the deficit from the appendages.

    Simultaneous use of more than one CTP product during the wound-care episode is not covered. A product change is allowed only within the applicable total application limit.

    Combination therapy with a CTP and other specialized wound technologies is not considered reasonable and necessary.

    Autologous platelet-rich plasma systems used to treat chronic nonhealing wounds are not reasonable and necessary except as described in NCD 270.3.

    CTP grafts are contraindicated in patients with known hypersensitivity to any component, including avian, bovine, porcine, or equine materials.

    Combination therapy with any CTP is not considered reasonable and necessary.

    Autologous PRP may be reasonable and necessary only under the exception described in NCD 270.3.

    Liquid or gel skin-substitute products or CTPs are not reasonable and necessary for ulcer care.

    A skin-substitute graft or CTP must not be placed on an infected, ischemic, or necrotic wound bed.

    Dermagraft is not medically necessary when the involved foot has inadequate blood supply.

    Applications of DermaCell or Oasis beyond 12 weeks are not medically necessary regardless of wound status.

    Oasis applications beyond 12 weeks are not medically necessary regardless of wound status.

    Repeat or alternative CTP applications are not medically reasonable and necessary when a previous full course was unsuccessful. Unsuccessful treatment includes an increase in ulcer size or depth, or no change from baseline with no sign that improvement is likely, for 4 weeks after therapy begins.

    Retreatment of healed ulcers, ulcers with greater than 75% size reduction and smaller than 0.5 cm², or wounds without a qualifying response is not medically reasonable and necessary.

    CTP therapy is contraindicated or not reasonable and necessary with active infection, osteomyelitis, uncontrolled diabetes, active Charcot arthropathy, inadequate circulation or ischemia, active vasculitis, continued tobacco smoking without physician-directed cessation efforts, or other inadequately controlled underlying conditions.

    More than 8 applications of a skin-substitute graft or CTP within an episode of care of up to 16 weeks are not reasonable and necessary.

    Repeat applications after unsuccessful treatment are not reasonable and necessary. Unsuccessful treatment includes increased size or depth, no measurable change from baseline, and no significant improvement or indication that closure is likely.

    Applications are not reasonable and necessary when underlying conditions or exacerbating factors are inadequately controlled, including uncontrolled diabetes, active infection, active Charcot arthropathy, vasculitis, or continued tobacco smoking without physician-directed cessation efforts.

    Re-treatment within 1 year of a CTP treatment course for the same venous stasis ulcer or diabetic neuropathic foot ulcer is considered treatment failure and does not meet reasonable-and-necessary criteria.

    Unlisted indications and products not listed in the policy are considered experimental, investigational, or unproven and are not covered.

    Covered Products, Codes, and Utilization Limits

    Breast reconstruction productsmixedCovered
    15777AlloDerm, AlloMax, Cortiva, DermACELL, or FlexHD used with covered medically necessary breast reconstruction
    Q4116AlloDerm, AlloMax, Cortiva, DermACELL, or FlexHD used with covered medically necessary breast reconstruction
    C1781AlloDerm, AlloMax, Cortiva, DermACELL, or FlexHD used with covered medically necessary breast reconstruction
    C9399AlloDerm, AlloMax, Cortiva, DermACELL, or FlexHD used with covered medically necessary breast reconstruction
    Q4128AlloDerm, AlloMax, Cortiva, DermACELL, or FlexHD used with covered medically necessary breast reconstruction
    Biobrane and Biobrane LmixedCovered
    15271-15278Biobrane or Biobrane L for temporary covering of a partial-thickness freshly debrided or excised burn wound
    C1849Biobrane or Biobrane L for temporary covering of a partial-thickness freshly debrided or excised burn wound
    EpicelmixedCovered
    15150-15157Epicel for FDA-approved HDE use in qualifying deep dermal or full-thickness burns
    C9399Epicel for FDA-approved HDE use in qualifying deep dermal or full-thickness burns
    Integra burn productsmixedCovered
    15271-15278Integra Dermal Regeneration Template, Integra Bilayer Matrix Wound Dressing, or Integra Meshed Bilayer Wound Matrix for qualifying burns
    Q4105Integra Dermal Regeneration Template, Integra Bilayer Matrix Wound Dressing, or Integra Meshed Bilayer Wound Matrix for qualifying burns
    Q4104Integra Dermal Regeneration Template, Integra Bilayer Matrix Wound Dressing, or Integra Meshed Bilayer Wound Matrix for qualifying burns
    Q4108Integra Dermal Regeneration Template, Integra Bilayer Matrix Wound Dressing, or Integra Meshed Bilayer Wound Matrix for qualifying burns
    C9363Integra Dermal Regeneration Template, Integra Bilayer Matrix Wound Dressing, or Integra Meshed Bilayer Wound Matrix for qualifying burns
    TranscytemixedCovered
    15271-15278Transcyte for temporary covering of a surgically excised deep partial- or full-thickness burn wound before autografting
    Q4182Transcyte for temporary covering of a surgically excised deep partial- or full-thickness burn wound before autografting
    ApligrafmixedCovered
    15275-15278Apligraf for qualifying diabetic foot ulcers and venous stasis ulcers
    Q4101Apligraf for qualifying diabetic foot ulcers and venous stasis ulcers
    AminoBandmixedCovered
    5275-15278AminoBand for qualifying diabetic foot ulcers and venous stasis ulcers
    Q4151AminoBand for qualifying diabetic foot ulcers and venous stasis ulcers
    Q4168AminoBand for qualifying diabetic foot ulcers and venous stasis ulcers
    DermagraftCPTCovered
    15275-15278Dermagraft for qualifying diabetic foot ulcers and wounds related to dystrophic epidermolysis bullosa
    AlloPatch (Pliable)CPTCovered
    15275-15278AlloPatch (Pliable) for qualifying diabetic foot ulcers
    AlloPatch and EpiFixHCPCSCovered
    Q4128AlloPatch (Pliable) and EpiFix Amniotic Membrane for qualifying ulcers
    EpiFix Amniotic MembraneCPTCovered
    15275-15278EpiFix Amniotic Membrane for qualifying diabetic foot and chronic venous ulcers
    DermaCellCPTCovered
    15275-15278DermaCell for qualifying neuropathic diabetic foot ulcers and oro-nasal fistula following cleft palate repair
    GrafixmixedCovered
    15275-15278Grafix for qualifying neuropathic diabetic foot ulcers
    Q4132Grafix for qualifying neuropathic diabetic foot ulcers
    Q4133Grafix for qualifying neuropathic diabetic foot ulcers
    Graft Jacket and Integra diabetic-foot productsmixedCovered
    15275-15278Graft Jacket Regenerative Tissue Matrix and Integra Dermal Regeneration Template/Integra Omnigraft Dermal Regeneration Template for qualifying indications
    Q4107Graft Jacket Regenerative Tissue Matrix for qualifying diabetic foot ulcers and oro-nasal fistula following cleft palate repair
    Q4105Integra Dermal Regeneration Template and Integra Omnigraft Dermal Regeneration Template for qualifying neuropathic diabetic foot ulcers
    Oasis wound Matrix and Ultra Tri-Layer MatrixmixedCovered
    15271-15278Oasis wound Matrix and Ultra Tri-Layer Matrix for qualifying diabetic foot and chronic venous ulcers
    Q4102Oasis wound Matrix and Ultra Tri-Layer Matrix for qualifying diabetic foot and chronic venous ulcers
    Q4124Oasis wound Matrix and Ultra Tri-Layer Matrix for qualifying diabetic foot and chronic venous ulcers
    Oasis wound Matrix, Ultra Tri-Layer MatrixCPT | HCPCSCovered
    15271-15278Oasis wound Matrix and Ultra Tri-Layer Matrix for qualifying diabetic foot and chronic venous ulcers
    Q4102Oasis wound Matrix and Ultra Tri-Layer Matrix for qualifying diabetic foot and chronic venous ulcers
    Q4124Oasis wound Matrix and Ultra Tri-Layer Matrix for qualifying diabetic foot and chronic venous ulcers
    Additional CPT/HCPCS codes approvable when criteria are metHCPCSCovered
    Q4431PMA skin substitute product, not otherwise specified, per square centimeter; list in addition to primary procedure
    Q4432510(k) skin substitute product, not otherwise specified, per square centimeter; list in addition to primary procedure
    Q4433361 HCT/P skin substitute product, not otherwise specified, per square centimeter; list in addition to primary procedure
    CPT codes for application of skin substitute graftsCPTCovered
    15271Application of skin substitute graft to the trunk, arms, or legs; first 25 sq cm or less
    15272Each additional 25 sq cm or part thereof; list separately in addition to code for primary procedure
    15273Application of skin substitute graft to the trunk, arms, or legs; first 100 sq cm or less, or 1% of body area of infants and children
    15274Each additional 100 sq cm or part thereof; list separately in addition to code for primary procedure
    15275Application of skin substitute graft to the face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 25 sq cm or less
    15276Each additional 25 sq cm or part thereof; list separately in addition to code for primary procedure
    15277Application of skin substitute graft to the face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children
    15278Each additional 100 sq cm or part thereof; list separately in addition to code for primary procedure
    HCPCS codes not coveredHCPCSNot Covered
    Q4159Affinity, per square centimeter
    Q4239Amnio-maxx or amnio-maxx lite, per square centimeter
    Q4368Amchothick, per square centimeter
    Q4369Amnioplast 3, per square centimeter
    Q4370Aeroguard, per square centimeter
    Q4371Neoguard, per square centimeter
    Q4372Amchoplast excel, per square centimeter
    Q4373Membrane wrap-lite, per square centimeter
    Q4375Duograft ac, per square centimeter
    Q4376Duograft aa, per square centimeter
    1–10 of 51
    1/6
    Epicel burn extent
    Burn depthDeep dermal or full-thickness burns
    Minimum burn extentTotal body surface area greater than or equal to 30%
    ProductEpicel used under the FDA-approved Humanitarian Device Exemption

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Commercial Authorization Required

    Commercial-member authorization applies to the listed tissue-engineered skin substitutes when requested for covered wound-care indications.

    • Verify that the requested product and indication appear in the policy before initiating treatment.
    Documentation Required

    Complete Pre-Service Medical Necessity Record

    Before initiating a specialized wound-therapy product, document medical necessity and a comprehensive treatment plan in the pre-service record.

    • Include the wound evaluation, failed standard-care measures, selected CTP product, planned procedure, risks, and complications.
    Documentation Required

    Policy Background

    Tissue-engineered skin substitutes are cellular or acellular matrices derived from human tissue, nonhuman tissue, synthetic materials, or combinations of these materials. They may provide temporary wound coverage or support wound closure and healing in burns, surgical wounds, diabetic foot ulcers, venous ulcers, and selected reconstructive conditions.

    Key Terms

    Tissue-engineered skin substitutes
    CompositionCellular or acellular matrices
    Source materialsHuman tissue, nonhuman tissue, synthetic materials, or a composite of these materials
    Manufacturing conceptSelected cells are generally seeded onto a matrix containing proteins and growth factors
    Bioengineered skin and soft-tissue substitutes
    Primary functionMatrices used for wound coverage, closure, and healing
    Clinical usesBurns, surgical wounds, diabetic ulcers, and venous ulcers
    Material types
    Policy Summary
    PayerSummaCare
    PolicyTissue-Engineered Skin Substitutes
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date02/12/2026
    Next Review DateN/A
    Key ActionBefore initiating specialized wound therapy, document chronicity, failed standard care, wound characteristics, medical necessity, and the planned product.
    SourceLink
    On This Page
    Covered Uses and Medical Necessity RequirementsCovered Products, Codes, and Utilization LimitsAuthorization, Documentation, and Denial RisksPolicy BackgroundKey Terms

    Not medically necessary when there is inadequate blood supply to the involved foot; contraindicated and without proven value in infected ulcers or ulcers with sinus tracts.

    Difficult-to-heal chronic partial- or full-thickness venous ulcer of the lower extremity that has failed standard wound therapy for at least 4 weeks.
  1. Initial treatment is limited to 3–4 applications.
  2. Additional applications may be made at least 1 week apart, up to 4 in 12 weeks, when evidence of wound healing is present.
  3. The treated lower extremity has adequate circulation and oxygenation to support healing, evidenced by a palpable pedal pulse or ABI of at least 0.70.
  4. Appropriate venous-stasis care has been provided, including control of edema, venous hypertension, or lymphedema; appropriate debridement; and documented diligent compression therapy using multilayer dressings, compression stockings exceeding 20 mmHg, or pneumatic compression.
  5. Initial treatment is limited to 3–4 applications.
  6. Additional applications may be made at least 1 week apart, up to a maximum of 4 applications in 12 weeks, only when evidence of wound healing is present.
  7. Applications beyond 12 weeks are not medically necessary regardless of wound status.
  8. The record documents a comprehensive treatment plan and the specific standard-care interventions that failed before CTP initiation.
  9. Appropriate wound care has addressed infection, edema or venous hypertension, debridement, off-loading for diabetic foot ulcers, and compression for venous stasis ulcers.
  10. Does not meet or exceed the patient's medical needs.
  11. At least as beneficial as an existing and available medically appropriate alternative.
  12. Placement on an infected, ischemic, or necrotic wound bed.
    Diabetic foot-ulcer duration
    Minimum durationGreater than 6 weeks
    Wound typeDiabetic foot ulcer, generally partial- or full-thickness
    Required care historyStandard wound therapy or standard diabetic-ulcer care must have failed
    Chronic venous-ulcer standard-therapy failure
    Minimum failed therapyAt least 4 weeks of standard or conservative wound therapy
    Venous-ulcer careRegular dressing changes and standard therapeutic compression may be required
    Wound statusThe ulcer must be chronic, difficult to heal, and noninfected where specified
    HbA1c
    HbA1c thresholdLess than 12%
    Applicable diabetes typesType 1 and type 2 diabetes
    Applies toAll diabetic foot-ulcer pathways in the policy
    Ankle-brachial index
    ABI thresholdAt least 0.70
    Alternative evidenceA palpable pedal pulse may also demonstrate adequate blood supply
    Applicable woundsSpecified diabetic foot and venous stasis ulcers
    Application limits
    Application rangeProduct-specific limits generally range from 4 to 8 applications in 12 weeks
    Additional applicationsRequire documented evidence of wound healing where specified
    TimingSome products require additional applications at intervals of at least one week
    Diabetic foot-ulcer duration
    Minimum durationGreater than 6 weeks
    Wound descriptionPartial- or full-thickness neuropathic diabetic foot ulcer
    Care prerequisiteUse in conjunction with standard diabetic-ulcer care
    Diabetic foot-ulcer initial applications
    Initial limitUp to 4 applications
    ProductOasis wound Matrix or Ultra Tri-Layer Matrix
    IndicationQualifying neuropathic diabetic foot ulcer
    Diabetic foot-ulcer additional applications
    IntervalAt least 1-week intervals
    12-week limitUp to 4 applications in 12 weeks
    Healing requirementEvidence of wound healing must be present
    Venous ulcer standard-care failure
    Minimum failed careAt least 4 weeks of standard wound therapy
    Ulcer typeDifficult-to-heal chronic venous partial- or full-thickness lower-extremity ulcer
    CirculationAdequate blood supply must be demonstrated by a palpable pedal pulse or ABI of at least 0.70
    Venous ulcer initial applications
    Initial limitUp to 3-4 applications
    ProductOasis wound Matrix or Ultra Tri-Layer Matrix
    IndicationQualifying chronic venous lower-extremity ulcer
    Venous ulcer additional applications
    IntervalAt least 1-week intervals
    12-week limitUp to 4 applications in 12 weeks
    Healing requirementEvidence of wound healing must be present
    HbA1c
    HbA1c thresholdLess than 12%
    Diabetes typesType 1 and type 2 diabetes
    ApplicationRequired for diabetic foot-ulcer treatment
    Adequate blood supply
    Adequate perfusionA palpable pedal pulse or ABI of at least 0.70
    Diabetic foot ulcersThe treated foot must have adequate blood supply
    Venous ulcersThe treated lower extremity must have adequate blood supply
    Medicare minimum skin-deficit size
    Minimum skin-deficit sizeAt least 1.0 cm²
    Wound typePartial- or full-thickness ulcer or skin deficit
    Wound bedA clean granular base is generally required
    Medicare circulation threshold
    ABI thresholdAt least 0.60
    Alternative circulation measureToe pressure greater than 30 mm Hg
    PurposeDemonstrates adequate circulation and oxygenation to support healing
    Maximum CTP applications
    Maximum treatment volume10 applications or treatments per wound episode and per 12-week period
    Product changesA product change may be allowed if the total application limit is not exceeded
    Multiple productsSimultaneous use of more than one product for the wound episode is not covered
    Typical chronic-wound treatment duration
    Typical durationNo more than 12 weeks
    ScopeTreatment of a chronic skin wound
    Utilization expectationTreatment must comply with product-specific FDA guidelines and application limits
    Maximum applications
    Application thresholdMore than 8 applications
    Episode durationEpisode of care of up to 16 weeks
    Coverage consequenceThe excess applications are not reasonable and necessary
    Retreatment interval
    Minimum retreatment intervalNo retreatment within 1 year
    Applicable ulcersThe same venous stasis ulcer or diabetic neuropathic foot ulcer
    Coverage consequenceRetreatment within 1 year does not meet reasonable-and-necessary criteria

    Standard Wound Care Is Required

    Use the covered product only with the applicable standard wound-care regimen and document patient compliance.

    • Standard care may include infection and edema control, debridement, off-loading, compression or limb elevation, appropriate dressings, glucose control, and tobacco-use management.
    Documentation Required

    Document Failure of Standard Wound Care

    Document an organized conservative-care course before CTP treatment and explain why the wound failed to respond. The record must show correction or management of applicable infection, edema, pressure, vascular, and other wound-related factors.

    • Address infection or colonization, edema or venous hypertension, off-loading, compression, debridement, wound protection, and relevant medical issues.
    • Document at least four weeks of appropriate care when required, including compliance and the specific interventions that failed.
    Documentation Required

    Document Wound and Treatment History

    Record the wound’s type, depth, duration, course, prior treatment, and current wound-bed findings before application.

    • Identify diabetic, venous, traumatic, burn, or other etiology; partial- or full-thickness involvement; exposed structures; infection; necrosis; exudate; sinus tracts; and the presence of a clean granular base.
    • Document prior dressings, compression, off-loading, debridement, infection treatment, and other conservative measures.
    Documentation Required

    Diabetic Foot-Ulcer Clinical Requirements

    For diabetic foot ulcers, document HbA1c below 12% and adequate perfusion of the treated foot.

    • Adequate supply under the product criteria is evidenced by a palpable pedal pulse or ABI of at least 0.70.
    Documentation Required

    Epicel HDE Documentation

    For Epicel, document the FDA-authorized HDE use and the extent and depth of the burn.

    • The covered indication is a deep dermal or full-thickness burn involving at least 30% of total body surface area.
    • Document whether Epicel is used with a split-thickness autograft or alone because autografting is not feasible.
    Documentation Required

    Coordinate Systemic Disease Management

    Ensure the patient is under the care of an appropriately licensed physician for the systemic disease causing or complicating the wound.

    • The medical record must identify the physician managing conditions such as diabetes, venous insufficiency, or neuropathy.
    • If another provider performs the CTP application, document that the provider is aware of the systemic condition and identify the managing physician.
    Documentation Required

    Record Baseline and Serial Measurements

    Document baseline wound measurements, measurements after at least four weeks of appropriate standard care, and measurements immediately before and after each CTP placement.

    • Record wound size and depth consistently so response to treatment can be evaluated.
    Documentation Required

    Monitor Response Every 30 Days

    Document the wound’s response to treatment at least every 30 days for each episode and retain the records for review.

    • Continuing treatment requires evidence that the wound is improving in response to the care provided.
    Documentation Required

    Explain Medical Necessity

    The pre-service record must explain why standard care failed, identify failed interventions, and establish why the selected skin-replacement procedure is medically necessary.

    • Include an updated medication history, relevant changes in medical problems, the planned procedure and product choice, and discussion of risks and complications.
    Documentation Required

    Document Smoking Cessation Measures

    When applicable, document smoking-cessation counseling and prescribed cessation measures before planned bioengineered skin-replacement therapy.

    • Continued tobacco use without a physician attempt to effect cessation may be a contraindication.
    Documentation Required

    Correct Wound Causes Before Application

    Before CTP therapy, document treatment and resolution of infection, osteomyelitis, foreign body, malignancy, cellulitis, and other underlying causes or aggravating processes.

    • Document appropriate debridement and control of edema, venous hypertension, lymphedema, infection or colonization, pressure, and other wound causes.
    • Diabetic foot ulcers require appropriate non-weight-bearing or off-loading; venous stasis ulcers require documented diligent compression when applicable.
    Documentation Required

    Maintain Complete Clinical Treatment Documentation

    Clinical records must establish the wound type and course, application history, response, and control of underlying conditions throughout treatment.

    • Document the wound’s etiology, depth, duration, prior and current therapy, product applications, healing response, and relevant systemic disease management.
    Documentation Required

    Verify FDA Product Eligibility

    Use only a product that satisfies applicable FDA requirements for the requested indication.

    • Eligibility may be based on FDA premarket approval, 510(k) clearance, or Humanitarian Device Exemption.
    • FDA approval alone does not establish coverage; product-specific FDA requirements for the indication must be met.
    Denial Risk

    Avoid Depth, Perfusion, and HbA1c Denial Risks

    Coverage is at risk when the ulcer has exposed tendon, muscle, joint capsule, or bone, or when perfusion or diabetic control is inadequate.

    • For the diabetic-foot-ulcer criteria, HbA1c must be less than 12% and the treated foot must have adequate blood supply.
    • The applicable product label may permit treatment of otherwise exposed structures, but the indication and label must be documented.
    Denial Risk

    Dermagraft Contraindications

    Dermagraft is not medically necessary for an inadequately perfused foot and is contraindicated or unproven for infected ulcers and ulcers with sinus tracts.

    • Use Dermagraft only for covered indications and with standard wound-care regimens.
    Denial Risk

    Do Not Extend DermaCell or Oasis Beyond 12 Weeks

    Applications beyond 12 weeks are not medically necessary for DermaCell or Oasis products, regardless of wound status.

    • Follow the product-specific application limits and intervals.
    Denial Risk

    Document Healing Before Additional Applications

    Additional applications require documented healing or improvement and compliance with the applicable product and episode limits.

    • Do not exceed product-specific limits, including the applicable maximum number of applications within 12 weeks.
    • Document evidence such as epithelialization, contraction, reduction in ulcer size, or progress toward closure.
    Denial Risk

    Dermagraft Requires Standard Wound Care

    Dermagraft requires use with standard wound-care regimens and is not established for infected or otherwise excluded ulcers.

    • Do not apply Dermagraft without documented standard care or when infection, sinus tracts, inadequate perfusion, or another exclusion is present.
    Denial Risk

    Use an Eligible Product in an Organized Wound Program

    Reimbursement requires an eligible product and a comprehensive, organized wound-management program documented in the medical record.

    • Products not FDA-labeled or cleared for the type of wound being treated are not reasonable and necessary and are not eligible for reimbursement.
    Denial Risk

    Avoid Excessive or Simultaneous Applications

    More than 10 applications or treatments for an episode, simultaneous use of multiple products, or use beyond the applicable limits is excluded.

    • A product change may be allowed during the episode, but the total number of applications must remain within the policy limit.
    Denial Risk

    Do Not Retreatment After an Unsuccessful Course

    Repeat or alternative treatment after an unsuccessful full course is not medically reasonable and necessary, including early retreatment within one year.

    • An unsuccessful course includes increased ulcer size or depth, no measurable baseline change, and no meaningful healing response.
    • A venous stasis or diabetic neuropathic foot ulcer generally may not be retreated within one year of a completed CTP course.
    Denial Risk

    Control Contraindicating Conditions

    Do not apply CTPs when underlying conditions or exacerbating factors are inadequately controlled.

    • Examples include uncontrolled diabetes, active infection, active Charcot arthropathy, vasculitis, ischemia, progressive necrosis, or continued tobacco smoking without physician-directed cessation efforts.
    Billing Rule

    Avoid Repeated Surgical Preparation

    Repeated surgical preparation services billed with CTP application codes are not reasonable and necessary.

    • Each wound is expected to receive appropriate preparation, generally at initiation of care before CTP placement, rather than repeated preparation with routine applications.
    Denial Risk

    Do Not Combine CTP Therapies

    Combination therapy with any CTP is not reasonable and necessary under the referenced coverage criteria.

    • Do not use more than one CTP simultaneously for the same wound episode.
    Denial Risk

    Screen for Product Hypersensitivity

    Do not use a CTP when the patient has known hypersensitivity to any component of the product.

    • Screen and document allergies to relevant components, including avian, bovine, porcine, or equine materials when applicable.
    Billing Rule

    Prepare the Wound Without Repeated Billing

    Each wound should receive appropriate preparation without repeated preparation services billed with CTP application codes.

    • Document the initial preparation and avoid billing routine, simple, or repeat preparation with subsequent CTP applications.
    Denial Risk

    Observe the One-Year Retreatment Interval

    The same venous stasis or diabetic neuropathic foot ulcer cannot generally be retreated with a CTP within one year of a completed course.

    • Document the prior course, completion date, and reason for any proposed retreatment.
    Denial Risk

    Avoid CTP Combination Therapy

    Combination therapy with any CTP is not reasonable and necessary.

    • Specialized wound technologies may be used only when separately reasonable and necessary; do not combine them with a CTP when excluded by the referenced LCD.
    Denial Risk

    Observe the Eight-Application Limit

    More than eight skin-substitute applications during an episode of up to 16 weeks is excluded under the referenced limitation.

    • Track the number of applications across products for the wound episode.
    Denial Risk

    Do Not Repeat an Unsuccessful Application

    Repeat application is excluded when the prior application was unsuccessful, including increased size or depth, no measurable change, or no healing response.

    • Document improvement before repeating an application.
    Denial Risk

    Confirm the Patient Is Clinically Suitable

    Application is excluded when conditions are inadequately controlled or a contraindication is present.

    • Do not apply to wounds with active infection, progressive necrosis, ischemia, active Charcot arthropathy, active vasculitis, or another contraindicating condition.
    Denial Risk

    Use a Suitable Wound Bed

    Do not place a graft or CTP on an infected, ischemic, or necrotic wound bed.

    • The wound should be clean, free of necrotic debris or exudate, adequately perfused, and prepared to support tissue growth and healing.
    Billing Rule

    Do Not Pair Preparation With Routine Replacement

    Surgical preparation performed with routine, simple, or repeat skin-replacement therapy is excluded.

    • Do not report preparation or debridement as an accompanying service when it is merely routine or repeated with CTP placement.
    Denial Risk

    Liquid and Gel Products Are Excluded

    Liquid or gel skin-substitute products or CTPs for ulcer care are not reasonable and necessary.

    • Verify that the requested product is an eligible covered graft or CTP form.
    Denial Risk

    Avoid Unlisted Uses and Products

    Unlisted indications and products not listed in the policy are considered experimental, investigational, or unproven.

    • Confirm that the product and requested indication match the policy’s listed coverage criteria before seeking authorization or billing.
    Cellular or acellular matrices derived from human, nonhuman, synthetic, or composite materials
    Autografts/tissue cultured autografts
    DefinitionAutologous skin grafts
    Tissue sourceThe patient’s own skin
    Included servicesHarvest or application of an autologous skin graft
    CTP grafts
    DefinitionNon-autologous cellular or tissue products applied over an open wound
    SourcesHuman, nonhuman, synthetic, or xenogeneic biological products
    PurposeAugment wound closure or skin growth
    Chronic wound
    DefinitionA wound that does not respond to standard wound treatment for at least 30 days
    Therapy settingOrganized, comprehensive conservative therapy
    DocumentationA comprehensive treatment plan is required before specialized wound therapy
    Failed response
    DefinitionFailure to respond to documented appropriate wound-care measures
    Possible progressionThe ulcer or skin deficit increases in size or depth
    No improvementThe wound remains unchanged without evidence that improvement is likely, such as granulation or epithelialization
    Human skin allografts
    DefinitionCTPs derived from donated human skin
    Cell treatmentIntact cells may be removed or treated to avoid immunologic rejection
    Intended functionsScaffolding, soft-tissue filling, growth-factor, hormonal, or enzymatic activity
    Allogeneic matrices
    SourceUsually derived from human neonatal fibroblasts
    Material formMay be derived from human tissue or membrane
    FunctionMay provide soft-tissue support and regenerative components
    Composite matrices
    Cellular componentsHuman keratinocytes and fibroblasts
    Support structureSynthetic mesh or xenogeneic collagen
    Biologic activityActive cellular components may generate bioactive compounds and proteins that support healing and epithelial regrowth
    Acellular matrices
    DefinitionMatrices derived from xenogeneic collagen, tissue, membranes, or cellular remnants
    Cell contentDerived from materials other than intact human skin
    FunctionProvide scaffolding and biologic activity to promote healing and wound closure
    Unsuccessful treatment
    Size or depthIncrease in ulcer size or depth
    MeasurementNo measurable change from baseline
    Clinical responseNo significant improvement or indication that significant improvement is likely, such as granulation or epithelialization
    Reasonable and necessary
    Safety and efficacyThe covered service must be safe and effective
    AppropriatenessIt must be appropriate in duration, frequency, setting, and accordance with accepted medical practice
    Alternatives and personnelIt must be furnished by qualified personnel, meet but not exceed medical needs, and be at least as beneficial as an available appropriate alternative